Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Accumulated Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Accumulated Expenses for 8 consecutive years, with $35.1 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 574.77% year-over-year to $35.1 million; the TTM value through Mar 2026 reached $35.1 million, up 574.77%, while the annual FY2025 figure was $18.3 million, 30.53% up from the prior year.
  • Accumulated Expenses hit $35.1 million in Q1 2026 for Kymera Therapeutics, up from $18.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $35.1 million in Q1 2026 and bottomed at $3.6 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $16.1 million, with a median of $14.0 million recorded in 2024.
  • Year-over-year, Accumulated Expenses soared 1538.56% in 2022 and then plummeted 82.71% in 2023.
  • Kymera Therapeutics' Accumulated Expenses stood at $8.1 million in 2022, then surged by 315.56% to $33.9 million in 2023, then tumbled by 58.58% to $14.0 million in 2024, then surged by 30.53% to $18.3 million in 2025, then surged by 91.66% to $35.1 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $35.1 million, $18.3 million, and $28.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.